Foresight Diagnostics Announces Multiple Presentations in Lymphoma Featuring PhasED-Seq™ Ultrasensitive MRD Analysis at the upcoming ASH Annual Meeting

Foresight Diagnostics, a leader in ultrasensitive minimal residual disease (MRD) detection technology, today announced the presentation of multiple lymphoma studies featuring Foresight CLARITY™ ...
American Association of Individual Investors

Why ADC Therapeutics SA’s (ADCT) Stock Is Down 8.63%

As of Wednesday, December 03, ADC Therapeutics SA’s ADCT share price has dipped by 8.63%, which has investors questioning if ...
Targeted Oncology

Axi-Cel Shows Durable Responses, Curative Hope in Non-Hodgkin Lymphoma

Axi-cel demonstrated a 90% overall response rate and 75% complete response rate in relapsed/refractory indolent non-Hodgkin lymphoma. Median progression-free survival was 62.2 months, with a median ...
Le Lézard

Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhibitor of MALT1, in Relapsed/Refractory ...

Aurigene Oncology Limited, a clinical-stage biopharmaceutical company developing novel therapies in oncology, today announced initial clinical results from 1st two cohorts of its ongoing Phase 1 ...
Le Lézard

Merck Data to be Presented at ASH 2025 Annual Meeting Showcase Continued Advancements in Hematology Pipeline and Novel Therapeutic Approaches

Merck , known as MSD outside of the United States and Canada, today announced that new data across multiple hematologic malignancies will be presented at the American Society of Hematology (ASH) ...
manilatimes

Enterome to present positive interim Phase 2 data for lead OncoMimics™ immunotherapy EO2463 in follicular lymphoma at American Society for Hematology (ASH) meeting

Enterome, a clinical-stage company pioneering OncoMimics™, a new class of off-the-shelf, multi-targeted in vivo immune therapies that induce a fast and potent expansion of memory T-cells to fight ...
BioSpace

6 Biotechs With a Shot at the FDA’s Platform Technology Designation

After revoking Sarepta’s award in July and awarding one to Krystal last month, the FDA’s platform technology designation program appears to be back on track. These six biotechs could be on the ...
Agence France-Presse

Incyte Announces More than 50 Abstracts Accepted for Presentation at the 2025 ASH Annual Meeting

Incyte (Nasdaq:INCY) today announced that data from key programs in its oncology portfolio will be presented in both oral and poster sessions at the 2025 American Society of Hematology (ASH) Annual ...
Malaysian Reserve

Hackensack Meridian John Theurer Cancer Center Unveils Research at the 67th American Society of Hematology Annual Meeting

HACKENSACK, N.J., Nov. 21, 2025 /PRNewswire/ — Investigators from Hackensack Meridian John Theurer Cancer Center (JTCC)—a leading research partner of the NCI-designated Lombardi Comprehensive Cancer ...
Opinion
The Desert ReviewOpinion

The Hidden Weapon Against Terminal Cancer

Diffuse large B-cell lymphoma (DLBCL) is an aggressive blood cancer that kills most untreated patients within one year. Standard CHOP chemotherapy improves five-year survival to 70%—still a ...

Foresight Diagnostics Announces Multiple Presentations in Lymphoma Featuring PhasED-Seq(TM) Ultrasensitive MRD Analysis at the upcoming ASH Annual Meeting

Foresight Diagnostics, a leader in ultrasensitive minimal residual disease (MRD) detection technology, today announced the presentation of multiple lymphoma studies featuring Foresight CLARITY(TM) ...
Healio

VIDEO: Potential treatment options emerge for patients with marginal zone lymphoma

Please provide your email address to receive an email when new articles are posted on . The results were presented at Society of Hematologic Oncology’s Annual Meeting. “We currently are really missing ...